BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17892461)

  • 1. Dendritic cell regeneration in the bone marrow of children treated for acute lymphoblastic leukaemia.
    Laane E; Björklund E; Mazur J; Lönnerholm G; Söderhäll S; Porwit A
    Scand J Immunol; 2007 Nov; 66(5):572-83. PubMed ID: 17892461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
    Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
    Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
    Ryan J; Quinn F; Meunier A; Boublikova L; Crampe M; Tewari P; O'Marcaigh A; Stallings R; Neat M; O'Meara A; Breatnach F; McCann S; Browne P; Smith O; Lawler M
    Br J Haematol; 2009 Jan; 144(1):107-15. PubMed ID: 19016726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
    Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
    Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
    Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.
    Laughton SJ; Ashton LJ; Kwan E; Norris MD; Haber M; Marshall GM
    J Clin Oncol; 2005 Apr; 23(10):2264-71. PubMed ID: 15800317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic HLA mismatched/ haploidentical hematopoietic stem cell transplantation].
    Wu JY; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Feb; 28(2):73-7. PubMed ID: 17650664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diphtheria (D) and tetanus (T) antibody values in children with acute lymphoblastic leukaemia (ALL) after treatment according to Co-ALL 05/92.
    Calaminus G; Hense B; Laws HJ; Groeger M; MacKenzie CR; Göbel U
    Klin Padiatr; 2007; 219(6):355-60. PubMed ID: 18050047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
    Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
    Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
    J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
    Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
    Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation of myeloid lineage cells and apoptosis of lymphoblastic leukemic cells induced by short-course high-dose methylprednisolone in patients with acute lymphoblastic leukemia.
    Yildiran A; Erduran E; Tekelioğlu Y; Dilber E; Gedik Y
    Turk J Pediatr; 2002; 44(2):116-21. PubMed ID: 12026198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
    Lönnerholm G; Thörn I; Sundström C; Frost BM; Abrahamsson J; Behrendtz M; Heldrup J; Jacobsson S; Li A; Olofsson T; Porwit A; Söderhäll S; Larsson R; Forestier E
    Leuk Res; 2009 Jan; 33(1):46-53. PubMed ID: 18639340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients.
    Maecker B; Mougiakakos D; Zimmermann M; Behrens M; Hollander S; Schrauder A; Schrappe M; Welte K; Klein C
    Leukemia; 2006 Apr; 20(4):645-9. PubMed ID: 16498391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells in bone marrow at diagnosis and after chemotherapy in adult patients with acute myeloid leukaemia.
    Derolf AR; Laane E; Björklund E; Saft L; Björkholm M; Porwit A
    Scand J Immunol; 2014 Dec; 80(6):424-31. PubMed ID: 25346147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.